Wobble Genomics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Wobble Genomics is an early-stage biotech (founded 2020) pioneering a liquid biopsy platform based on full-length, long-read RNA sequencing. Its core technologies, Level-Up (biochemical) and TAMA (bioinformatics), are designed to unlock and analyze low-abundance RNA from blood, revealing novel biomarkers for cancer. The company has presented early validation data at major conferences (SABCS 2025, ESMO 2025), demonstrating application in breast cancer (HER2 profiling) and platform robustness. It operates as a private, pre-revenue diagnostics platform company targeting a significant opportunity in non-invasive cancer testing.

Oncology

Technology Platform

A dual-component platform combining 'Level-Up' (a biochemical technology for capturing low-abundance, full-length RNA from blood) and 'TAMA' (a bioinformatics software for analyzing long-read RNA sequencing data), integrated with long-read sequencing to discover and detect novel RNA biomarkers.

Opportunities

The platform targets the large and growing liquid biopsy market by offering a novel RNA-based approach that could provide higher sensitivity and access to new biomarkers compared to current ctDNA-based tests.

Successful validation, particularly in therapy selection like HER2 testing, provides a clear pathway to initial clinical adoption and revenue.

Risk Factors

The company faces significant technical risk in proving the clinical utility of its novel RNA biomarkers at scale.

As a pre-revenue, early-stage diagnostics developer, it also faces substantial commercialization, regulatory, and competitive risks in a crowded market, with a high dependence on securing ongoing funding.

Competitive Landscape

Wobble Genomics competes in the crowded liquid biopsy space dominated by large players like Guardant Health and Grail (primarily ctDNA-focused) and other RNA-focused startups. Its key differentiator is the focus on full-length, low-abundance RNA via long-read sequencing, a niche with fewer established competitors but unproven clinical impact.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →